CStone Pharmaceuticals, a Chinese clinical-stage biopharmaceutical company, has raised about HK$2.23 billion (US$284.09 million) in an initial public offering on the Hong Kong stock exchange on Tuesday, which makes it become the sixth pre-profit Chinese biotech company to float shares in the financial hub.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?